Waldenstrom Macroglobulinemia - Pipeline Review, H1 2015

Published: Apr, 2015 | Pages: 199 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Waldenstrom Macroglobulinemia - Pipeline Review, H1 2015

Summary 

Global Markets Direct's, 'Waldenstrom Macroglobulinemia - Pipeline Review, H1 2015', provides an overview of the Waldenstrom Macroglobulinemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Waldenstrom Macroglobulinemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Waldenstrom Macroglobulinemia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Waldenstrom Macroglobulinemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Waldenstrom Macroglobulinemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Waldenstrom Macroglobulinemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Waldenstrom Macroglobulinemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reason To Buy 

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Waldenstrom Macroglobulinemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Waldenstrom Macroglobulinemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Waldenstrom Macroglobulinemia Overview 9
Therapeutics Development 10
Pipeline Products for Waldenstrom Macroglobulinemia - Overview 10
Pipeline Products for Waldenstrom Macroglobulinemia - Comparative Analysis 11
Waldenstrom Macroglobulinemia - Therapeutics under Development by Companies 12
Waldenstrom Macroglobulinemia - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Waldenstrom Macroglobulinemia - Products under Development by Companies 17
Waldenstrom Macroglobulinemia - Companies Involved in Therapeutics Development 19
AbbVie Inc. 19
arGEN-X BV 20
Bayer AG 21
Calithera Biosciences, Inc. 22
Celgene Corporation 23
Genmab A/S 24
Gilead Sciences, Inc. 25
Idera Pharmaceuticals, Inc. 26
Immune System Therapeutics Ltd. 27
Incyte Corporation 28
Karyopharm Therapeutics, Inc. 29
Merck KGaA 30
Millennium Pharmaceuticals, Inc. 31
Nimbus Therapeutics, LLC 32
Nordic Nanovector AS 33
Novartis AG 34
Onyx Pharmaceuticals, Inc. 35
Pharmacyclics, Inc. 36
Waldenstrom Macroglobulinemia - Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Target 38
Assessment by Mechanism of Action 40
Assessment by Route of Administration 42
Assessment by Molecule Type 44
Drug Profiles 46
ACP-196 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
ARGX-110 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Betalutin - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
carfilzomib - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
CB-839 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
copanlisib - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
DI-B4 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
everolimus - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
FV-162 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
FV-214 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
GS-9973 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
ibrutinib - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
idelalisib - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
IMO-8400 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
INCB-39110 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
INCB-40093 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
IST-1097 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
ixazomib citrate - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
lenalidomide - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
ofatumumab - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
oprozomib - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
pevonedistat hydrochloride - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
sapanisertib - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
selinexor - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
Small Molecules to Inhibit IRAK4 for Immunology and Oncology - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
spebrutinib besylate - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
venetoclax - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
Waldenstrom Macroglobulinemia - Recent Pipeline Updates 115
Waldenstrom Macroglobulinemia - Dormant Projects 188
Waldenstrom Macroglobulinemia - Dormant Projects 188
Waldenstrom Macroglobulinemia - Discontinued Products 189
Waldenstrom Macroglobulinemia - Product Development Milestones 190
Featured News & Press Releases 190
Apr 09, 2015: New Longer-Term IMBRUVICA (ibrutinib) Data Show High Response Rates in Patients with Waldenstrom's Macroglobulinemia 190
Jan 29, 2015: U.S. FDA Approves IMBRUVICA (ibrutinib) for the Treatment of Waldenstrom's Macroglobulinemia: First FDA-Approved Therapy for This Disease 191
Dec 22, 2014: Pharmacyclics Announces Update on IMBRUVICA (ibrutinib) Waldenstrom's macroglobulinemia Submission 192
Dec 01, 2014: New IMBRUVICA (ibrutinib) Application Accepted by European Medicines Agency for Waldenstrom's Macroglobulinemia 192
Nov 03, 2014: arGEN-X Submits Investigational New Drug Application to Evaluate ARGX-110 in Waldenstr�m's Macroglobulinemia 193
Oct 20, 2014: IMBRUVICA (ibrutinib) Supplemental New Drug Application Submitted to the U.S. FDA for Waldenstrom's macroglobulinemia 193
Jun 10, 2014: arGEN-X and the Leukemia & Lymphoma Society Partner on the Development of ARGX-110 for the Treatment of Waldenstr�m's Macroglobulinemia 194
Nov 07, 2013: Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations On Oprozomib at 55th American Society of Hematology Annual Meeting 195
Jun 20, 2013: Pharmacyclics Presents Ibrutinib Monotherapy Clinical Trial Data In Patients With Waldenstrom's Macroglobulinemia At ICML 195
Apr 01, 2013: Onyx Pharma To Present Data On Oprozomib At 14th International Myeloma Workshop 196
Appendix 198
Methodology 198
Coverage 198
Secondary Research 198
Primary Research 198
Expert Panel Validation 198
Contact Us 198
Disclaimer 199

List of Tables

Number of Products under Development for Waldenstrom Macroglobulinemia, H1 2015 10
Number of Products under Development for Waldenstrom Macroglobulinemia - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 13
Comparative Analysis by Late Stage Development, H1 2015 14
Comparative Analysis by Clinical Stage Development, H1 2015 15
Comparative Analysis by Early Stage Development, H1 2015 16
Products under Development by Companies, H1 2015 17
Products under Development by Companies, H1 2015 (Contd..1) 18
Waldenstrom Macroglobulinemia - Pipeline by AbbVie Inc., H1 2015 19
Waldenstrom Macroglobulinemia - Pipeline by arGEN-X BV, H1 2015 20
Waldenstrom Macroglobulinemia - Pipeline by Bayer AG, H1 2015 21
Waldenstrom Macroglobulinemia - Pipeline by Calithera Biosciences, Inc., H1 2015 22
Waldenstrom Macroglobulinemia - Pipeline by Celgene Corporation, H1 2015 23
Waldenstrom Macroglobulinemia - Pipeline by Genmab A/S, H1 2015 24
Waldenstrom Macroglobulinemia - Pipeline by Gilead Sciences, Inc., H1 2015 25
Waldenstrom Macroglobulinemia - Pipeline by Idera Pharmaceuticals, Inc., H1 2015 26
Waldenstrom Macroglobulinemia - Pipeline by Immune System Therapeutics Ltd., H1 2015 27
Waldenstrom Macroglobulinemia - Pipeline by Incyte Corporation, H1 2015 28
Waldenstrom Macroglobulinemia - Pipeline by Karyopharm Therapeutics, Inc., H1 2015 29
Waldenstrom Macroglobulinemia - Pipeline by Merck KGaA, H1 2015 30
Waldenstrom Macroglobulinemia - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 31
Waldenstrom Macroglobulinemia - Pipeline by Nimbus Therapeutics, LLC, H1 2015 32
Waldenstrom Macroglobulinemia - Pipeline by Nordic Nanovector AS, H1 2015 33
Waldenstrom Macroglobulinemia - Pipeline by Novartis AG, H1 2015 34
Waldenstrom Macroglobulinemia - Pipeline by Onyx Pharmaceuticals, Inc., H1 2015 35
Waldenstrom Macroglobulinemia - Pipeline by Pharmacyclics, Inc., H1 2015 36
Assessment by Monotherapy Products, H1 2015 37
Number of Products by Stage and Target, H1 2015 39
Number of Products by Stage and Mechanism of Action, H1 2015 41
Number of Products by Stage and Route of Administration, H1 2015 43
Number of Products by Stage and Molecule Type, H1 2015 45
Waldenstrom Macroglobulinemia Therapeutics - Recent Pipeline Updates, H1 2015 115
Waldenstrom Macroglobulinemia - Dormant Projects, H1 2015 188
Waldenstrom Macroglobulinemia - Discontinued Products, H1 2015 189